To assess the impact of combination therapy, they employed anti-PD-1 treatment in conjunction with the Gal-1 inhibitor OTX008, examining its effects on tumor growth in LLC and B16-F10 tumor models. The gene discussed is LGALS1; the disease is neoplasm.